Opus Genetics (IRD) Assets (2010 - 2026)
Opus Genetics (IRD) posted quarterly Assets of $66.8 million for Q1 2026, up 38.66% year-over-year from $48.2 million in Q1 2025, and up 32.93% quarter-over-quarter from $50.2 million in Q4 2025.
Opus Genetics (IRD) Assets (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Assets for 17 consecutive years, with $66.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 38.66% year-over-year to $66.8 million; the TTM figure through Mar 2026 stood at $66.8 million (up 38.66% YoY), while the FY2025 annual figure was $50.2 million, up 36.3% from the prior year.
- Assets climbed to $66.8 million in Q1 2026 per IRD's latest filing, from $50.2 million in the prior quarter.
- Across five years, Assets topped out at $66.8 million in Q1 2026 and bottomed at $14.6 million in Q3 2022.
- Historically, Assets has averaged $41.9 million across 5 years, with a median of $44.8 million in 2024.
- Annual changes were most pronounced in 2022 — Assets sank 37.22% — and 2023, when it surged 271.99%.
- Opus Genetics' Assets stood at $49.0 million in 2022, then grew by 10.12% to $53.9 million in 2023, then sank by 31.67% to $36.9 million in 2024, then surged by 36.3% to $50.2 million in 2025, then jumped by 32.93% to $66.8 million in 2026.
- Business Quant data shows IRD's Assets at $66.8 million in Q1 2026, $50.2 million in Q4 2025, and $36.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 92.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.97 Mn |
| Mar 31, 2026 | 66.79 Mn |
| Dec 31, 2025 | 50.24 Mn |
| Sep 30, 2025 | 36.12 Mn |
| Jun 30, 2025 | 38.67 Mn |
| Mar 31, 2025 | 48.17 Mn |
| Dec 31, 2024 | 36.86 Mn |
| Sep 30, 2024 | 40.39 Mn |
| Jun 30, 2024 | 44.83 Mn |
| Mar 31, 2024 | 51.84 Mn |
| Dec 31, 2023 | 53.95 Mn |
| Sep 30, 2023 | 54.19 Mn |
| Jun 30, 2023 | 43.47 Mn |
| Mar 31, 2023 | 45.40 Mn |
| Dec 31, 2022 | 48.99 Mn |
| Sep 30, 2022 | 14.57 Mn |
| Jun 30, 2022 | 17.90 Mn |
| Mar 31, 2022 | 20.49 Mn |
| Dec 31, 2021 | 26.08 Mn |
| Sep 30, 2021 | 23.20 Mn |